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Abstract
Background: This study addresses involvement of major 5-fluorouracil (5-FU) pathway genes in the prognosis of
colorectal carcinoma patients.
Methods: Testing set and two validation sets comprising paired tumor and adjacent mucosa tissue samples from
151 patients were used for transcript profiling of 15 5-FU pathway genes by quantitative real-time PCR and DNA
methylation profiling by high resolution melting analysis. Intratumoral molecular profiles were correlated with
clinical data of patients. Protein levels of two most relevant candidate markers were assessed by immunoblotting.
Results: Downregulation of DPYD and upregulation of PPAT, UMPS, RRM2, and SLC29A1 transcripts were found
in tumors compared to adjacent mucosa in testing and validation sets of patients. Low RRM2 transcript level
significantly associated with poor response to the first-line palliative 5-FU-based chemotherapy in the testing
set and with poor disease-free interval of patients in the validation set irrespective of 5-FU treatment. UPP2 was
strongly methylated while its transcript absent in both tumors and adjacent mucosa. DPYS methylation level
was significantly higher in tumor tissues compared to adjacent mucosa samples. Low intratumoral level of UPB1
methylation was prognostic for poor disease-free interval of the patients (P = 0.0002). The rest of the studied 5-FU
genes were not methylated in tumors or adjacent mucosa.
Conclusions: The observed overexpression of several 5-FU activating genes and DPYD downregulation deduce
that chemotherapy naïve colorectal tumors share favorable gene expression profile for 5-FU therapy. Low RRM2
transcript and UPB1 methylation levels present separate poor prognosis factors for colorectal carcinoma patients
and should be further investigated.
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Background
Colorectal carcinoma (OMIM: 114500) is the third most
common malignancy and the fourth cause of cancer-
related deaths in the adult population worldwide, with
the highest incidence recorded in Central Europe [1, 2].
Colorectal cancer treatment consists of surgical re-
moval of the tumor and, based on disease characteristics,
of chemo- and or radiotherapy. 5-Fluorouracil (5-FU) is
widely used drug in the first-line therapy of colorectal
cancer [3]. Over 80 % of administered 5-FU dose is
rapidly degraded [4] and only 1–3 % is converted into its
active metabolite fluorodeoxyuridine monophosphate
(FdUMP [5],). FdUMP then inhibits thymidylate syn-
thase (TYMS, OMIM: 188350) and blocks deoxythymi-
dine triphosphate (dTTP) synthesis. Subsequent dTTP
depletion triggers “thymineless” death [6]. TYMS is con-
sidered as a potential prognostic marker for colorectal
cancer. Recent studies have shown that overexpression
of TYMS transcript predicts poor outcome in colorectal
cancer patients [7, 8]. However, another contemporary
study has not confirmed these observations as intratu-
moral TYMS transcript level was not predictive in
patients with colorectal cancer of stage II and III [9].
Several studies have indicated potential prognostic or
predictive role of 5-FU metabolizing enzymes expression
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for resistance to the treatment of colorectal cancer.
Colorectal cancer patients with low protein expression
of 5-FU inactivating enzyme dihydropyrimidine de-
hydrogenase (DPYD, OMIM: 612778) exhibited a longer
survival after 5-FU-treatment than those with high levels
[10]. Likewise, high DPYD transcript level was associated
with poor outcome of stage IV colorectal cancer patients
[11]. High thymidine phosphorylase (TYMP, OMIM:
131222, 5-FU activating enzyme) transcript level was as-
sociated with significantly better disease-free survival
(DFS) following oral administration of 5-FU in stage III
colorectal cancer patients [12].
The resistance of the tumor cells towards 5-FU is
substantially modulated by the transport mechanisms.
Especially solute carrier transporter 29A1 (SLC29A1,
OMIM: 602193) plays a crucial role in cellular uptake
of nucleoside drugs such as cytarabine, gemcitabine, or
5-FU [13]. Results of a recent small scale functional
study suggested that high SLC29A1 mRNA levels in
colorectal cancer tumor tissue correlate with poor clinical
response to 5-FU [14].
In this study we aimed to address importance of gene
expression and methylation profile of 15 5-FU genes in
tumor and adjacent bowel mucosa tissues of colorectal
cancer patients for the patient’s prognosis and the
response to 5-FU. Genes were selected from literature and
PharmGKB database based on functional evidence from 5-
FU pharmacokinetics data (https://www.pharmgkb.org/).
Protein expression of two most relevant candidate markers
was assessed as another chain underlying 5-FU mode
of action.
Methods
Studied patients and collection of biological specimen
Tumor tissue and adjacent non-neoplastic mucosa sam-
ples were obtained from total of 151 patients with spor-
adic colorectal cancer (C18-21 according to ICD-10)
diagnosed at the Department of Surgery and Oncology,
Teaching Hospital and Medical School in Pilsen, and
General Teaching Hospital in Prague between January
2008 and November 2011. From 151 patients, 146 paired
tissue samples (tumor and control mucosa), four tumors,
and one mucosa sample were taken for analyses (for
study flow chart, see Fig. 1). Native tissue samples were
collected as described elsewhere [15, 16].
Patients represented three groups – testing set (stage
II-IV, n = 52) for gene and protein expression and
methylation analysis, validation set I (stage II, n = 67) for
gene expression analysis, and validation set II (stage II
and III, n = 32) for gene expression and methylation
analysis. The lack of tissue aliquots for simultaneous
isolation of RNA and DNA necessitated the use of
two different validation sets. All patients in the test-
ing set underwent adjuvant (n = 26) or palliative (n = 26)
chemotherapy regimens based on 5-FU (with added
leucovorin and/or oxaliplatin). In the validation sets I and
II, 24 and 17 patients were treated by such chemotherapy
regimens, respectively (Table 1 and Fig. 1).
Response to the palliative treatment was evaluated by
RECIST criteria [17] based on routine imaging tech-
niques for assessment of tumor mass (computerized
tomography with or without positron emission, magnetic
resonance or ultrasonography). Increase in tumor mass
or the appearance of new lesions in patients with pallia-
tive treatment indicated progression and thus poor re-
sponse to the treatment (PD). Good response to the
treatment was defined as a decrease of the number or
volume of metastases, i.e., complete or partial response
(CR or PR) or stabilization of the disease or (SD). In
patients treated by adjuvant therapy after radical surgical
resection R0 disease-free interval (DFI) served as a
measure of the treatment outcome. DFI was defined as
the time elapsed between radical surgical R0 resection
and disease recurrence.
Methylation analyses were conducted on 22 tissue
pairs from the testing set and on the whole independent
validation set II from the General Teaching Hospital,
Prague.
Isolation of total RNA and cDNA synthesis
Total RNA was isolated from frozen tissues using Trizol®
reagent (Life Technologies, Carslbad, CA), stored, and
characterized for the quantity and quality [18]. Comple-
mentary DNA (cDNA) was synthesized using 0.5 μg of
total RNA and random hexamer primers with help of
RevertAid™ First Strand cDNA Synthesis Kit (MBI
Fermentas, Vilnius, Lithuania). Quality of cDNA in
terms of DNA contamination was confirmed by PCR
amplification of ubiquitin C [19].
Gene expression profiling
Quantitative real-time PCR (qPCR) was performed using
ViiA7 Real-Time PCR System, TaqMan® Gene Expres-
sion Assays and TaqMan® Gene Expression Master Mix
(Life Technologies). Reference genes - POLR2A (DNA-
directed RNA polymerase II subunit A, OMIM: 180660),
MRPL19 (mitochondrial ribosomal protein L19, OMIM:
611832), EIF2B1 (eukaryotic translation initiation factor
2B, subunit 1, OMIM: 606686), and PSMC4 (proteasome
26S subunit, ATPase, 4, OMIM: 602707) - were selected
by us earlier [15]. Gene Expression Assays with their
characteristics are listed in Additional file 1: Table S1.
While samples from the testing set were preamplified
using TaqMan PreAmp Master Mix (Life Technologies),
cDNA from the validation sets was used for quantifica-
tion directly without preamplification procedure [20].
For calculating the qPCR efficiency of each assay, a
calibration curve from one non-neoplastic sample was
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prepared (six points, 5-times dilution). The non-template
control contained water instead of cDNA.
The qPCR study design adhered to the MIQE Guide-
lines (Minimum Information for Publication of Quanti-
tative Real-Time PCR Experiments [21]).
Gene expression and clinical data of all samples were
submitted to Gene Expression Omnibus (GEO) reposi-
tory under accession number GSE67111.
Promoter CpG methylation profiling
To convert unmethylated cytosines to uracils whole gen-
omic DNA was treated with sodium bisulfite using the
Epitect Bisulfite Kit (Qiagen, Hilden, Germany) following
the manufacturer’s protocol. Promoter region of every
gene of interest was determined using Genomatix
MatInspector and Genes & Genomes software (Geno-
matix Software GmbH, Munich, Germany). CpG islands
or simple CpG sites were identified by Methyl Primer
Express Software v1.0 (Applied Biosystems, Foster City,
CA). The same software was used for design of primers
specific for sodium bisulfite converted DNA bases.
Number of CpGs in the PCR amplicon and equal primer
melting temperature (Tm) were taken into consideration
in the primer design. Real-time PCR followed by high
resolution melting (HRM) was carried out in high-
performance Eco Real-Time PCR system (Illumina, San
Diego, CA), essentially as described in [16]. PCR was ini-
tiated by incubation at 95 °C for 5 min, followed by
50 cycles at 95 °C for 10 s, annealing temperature of
specific primers (Ta) for 20 s, and 72 °C for 10 s. Primer
sequences, Tm, Ta, length, and numbers of CpGs for
each amplicon are listed in Additional file 1: Table S2.
HRM thermal profile was set up according to the
manufacturer’s recommendations (Qiagen). Fluorescence
data were converted into melting peaks by the Eco Soft-
ware (Illumina, Ver. 3.0.16.0). For each assay, a standard
dilution series of EpiTect Control DNAs (Qiagen) was
run to assess the quantitative properties and sensitivity
of the assay. Fluorescence of each sample was normalized
against 100 % methylated DNA control. Methylation data
of individual samples were subtracted from calibration
curve with positive controls of 100, 75, 50, 25, and 0 %
methylated DNA.
Immunoblotting in human colorectal cancer tissues
Tissue sample pairs from 15 patients and unpaired tumors
from two patients were selected based on tissue availabil-
ity from the testing set and used for immunoblotting.
Samples, stored at −80 °C prior to the protein isolation,
were grinded by a mortar and pestle, subsequently protein
and total RNA were isolated using 50 mM Tris–HCl,
150 mM NaCl, 10 % Triton X-100 buffer. Protein concen-
tration was determined by bicinchoninic acid assay
(Thermo Scientific Pierce Protein Research Products,
Rockford, IL). Immunoblotting was performed as de-
scribed in [20, 22]. Briefly, 10 μg of protein was used for
separation by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (10 %) and transferred onto 0.2 μm
Protran nitrocellulose membrane (Whatman, Kent, UK).
Primary antibodies against dihydropyrimidinase (DPYS,
OMIM: 613326) (dilution 1:4000), beta-ureidopropionase
(UPB1 OMIM: 606673) (dilution 1:500) (both from Aviva
System Biology, San Diego, CA), β-actin (dilution 1:2000;
Sigma-Aldrich, St. Louis, MO) and the corresponding
horseradish-peroxidase-conjugated secondary antibodies
(dilution 1:10000; Sigma-Aldrich) were employed. Protein
Fig. 1 Flow chart of the study. Samples flow and experimental data are displayed by dashed lines and statistical analyses by solid lines. Numbers
of 5-FU treated patients in red rectangles and untreated patients in blue rectangles
Kunicka et al. BMC Cancer  (2016) 16:795 Page 3 of 12
bands were visualized with an enhanced chemilumin-
escence detection system (Pierce Biotechnology) by
Fc Odyssey (Licor Biotechnology, Lincoln, NE) and
quantified by densitometry (Image Studio software,
Licor Biotechnology).
Statistical analyses
Expression levels of genes were analyzed by ViiA7
System Software (Life Technologies) and statistical
analysis was performed using SPSS v16.0 Software
(SPSS Inc., Chicago, IL). Fold changes were calculated
usig raw cycle threshold (Ct) data by the REST2009
program (Qiagen), which is routinely used for the deter-
mination of differences between different types of sample
and control groups and considers both normalization to
numerous reference genes and reaction efficiencies [23].
Then ratios of Ct values of genes of interest and mean
value of reference genes were calculated and used for
further statistical analyses. Differences in gene expression
or methylation levels between tumor and control tissues
were assessed by the nonparametric Mann-Whitney
U-test. To evaluate associations of transcript levels
with clinical data and other variables (Table 1), nonpara-
metric tests (the Kruskal-Wallis, the Mann-Whitney, and
the Spearman’s tests) were used.
DFI was evaluated by the Kaplan-Meier method and
the Log Rank test was used for evaluation of the com-
pared subgroups and combined groups of patients.
Stage-adjusted analysis was performed by the Cox re-
gression. All P-values were calculated from two-sided
tests. P-values lower than 0.05 were considered statisti-
cally significant. The correction for multiple testing was
applied according to Bonferroni.
Results
Patients’ characteristics
Summary of patient’s characteristics and clinical data
from testing and validation sets are presented in Table 1
and the study flow diagram in Fig. 1. Testing set com-
prised colorectal cancer patients with stages UICC II-IV
treated by first-line adjuvant (n = 26, UICC II and III)
and palliative chemotherapy based on 5-FU (n = 26,
UICC IV). Testing set served as a hypothesis generating
screen and for assessment of protein levels. Validation
set I used for validation of gene expression study in-
cluded patients with UICC II stage (n = 67). Part of them
was treated by 5-FU-based chemotherapy (n = 24). Valid-
ation set II used for methylation study consisted of
patients with UICC II and III stage (n = 32) with 17
patients treated by 5-FU-based chemotherapy. The valid-
ation set II served for validation of correlations between
DPYS and UPB1 methylation and expression levels and
clinical data, mainly DFI. Median DFI of the validation
set I was 46 ± 6 months and that of the validation set II
was 39 ± 3 months.
Transcript levels in tumors and non-neoplastic control
tissues
Phosphoribosylpyrophosphate amidotransferase (PPAT,
OMIM: 172450), uridine monophosphate synthetase
(UMPS OMIM: 613891), ribonucleotide reductase M2
(RRM2, OMIM: 180390), and SLC29A1 transcripts were
consistently overexpressed in tumors compared to adja-
cent mucosa in both testing and validation I sets (except
UMPS, all passed the correction for multiple testing,
Table 1 Clinical-pathological characteristics of studied groups
of patients
Characteristics Testing set Validation set I Validation set II




Age at diagnosisa 63.9 ± 9.2 years 70.2 ± 9.5 years 70.8 ± 11.2 years
Tumor size (pT)
pT2 3 - 4
pT3 40 62 24
pT4 9 5 4
Presence of lymph node metastasis (pN)
pN0 15 67 18
pN1-2 37 - 14
Presence of distant metastasis (pM)
pM0 26 67 32
pM1 26 - -
Stage
UICC II 8 67 18
UICC III 18 - 14
UICC IV 26 - -
Histological grade (G)b
GI 6 9 6
GII 39 47 19
GIII 7 8 3
Gx - 3 4
Primary localization
Colon 26 44 28
Rectosigmoideum 12 9 1
Rectum 14 14 3
Chemotherapy
5-FU-based 52 24c 17
None - 33c 15
Footnotes:
aMedian ± standard deviation
bGI well differentiated, GII moderately differentiated, GIII poorly differentiated,
Gx cannot be assessed
cNumbers may not add up to 67 of available subjects because of missing
data (n = 10)
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Table 2a, Additional file 1: Table S1). On the contrary,
DPYD was downregulated in tumors compared to adja-
cent mucosa (P < 0.001, both sets).
Associations of transcript levels with clinical data of
patients
We first tested associations between gene expression
levels and therapy response of stage IV patients. Patients
from the testing set with poor response to the first-line
palliative treatment with 5-FU-based regimens had
significantly lower expression of UMPS, ribonucleotide re-
ductase M1 (RRM1, OMIM: 180410), and RRM2 in adja-
cent mucosa (n = 26; P = 0.024, P = 0.014, and P = 0.038,
respectively; none passed the correction for multiple
testing) than good responders (Table 3). Stage IV patients
were excluded from subsequent survival analyses due to
the metastatic character of their disease, which strongly
modifies their prognosis.
For DFI analyses, transcript levels were first divided
by their median separately in testing and validation
set I and for the combined analysis these data were
put together to eliminate raw data differences be-
tween sets. Significance of RRM2 gene expression for
prognosis of colorectal cancer patients was further
corroborated in the validation set I, where patients
with intratumoral RRM2 transcript level higher than
Table 2 Differences in transcript (A) and methylation (B) levels between tumor and adjacent mucosa tissues of colorectal cancer patients
Footnotes:
aAnalyzed by the Mann-Whitney test
bFold changes calculated by the REST2009 program
cResults, which passed correction for multiple testing
dMean ± standard deviation of percentage of sample methylation normalized to positive control (Methods)
ND not determined
Results from the testing set that have been confirmed in the validation set of patients are depicted in grey
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median had significantly longer DFI compared to patients
with levels below the median (n = 66, P = 0.009, did not
pass the correction for multiple testing, Fig. 2a, the rest of
results in Additional file 1: Figure S2). A non-significant
association in the same direction, was observed in the
testing set (n = 26, Additional file 1: Figure S3). Analysis of
the combined testing and validation I sets supported
the findings of the validation set I for RRM2 (n = 92,
P = 0.006, did not pass the correction for multiple testing,
Fig. 2b, the rest of results provided in Additional file 1:
Figure S4). This association was significant also in stage-
adjusted analysis by the Cox regression of the combined
set (n = 92, P = 0.013, HR = 4.17, 95 % CI = 1.35-12.50, for
all results see Additional file 1: Table S3).
Then the combined set was analyzed in respect to
chemotherapy by 5-FU containing regimens (n = 50).
However, in the combined analysis of 5-FU-treated
patients from the testing and validation I sets, neither
RRM2 transcript level (P = 0.301) nor levels of the
rest of genes did significantly associate with DFI
(Additional file 1: Figure S5). Stage-adjusted analysis
has shown significant association between UPB1 and
DFI (P = 0.047, HR = 0.25, 95 % CI = 0.06–0.98, for all
results see Additional file 1: Table S3), which was
not significant in the univariate analysis (P = 0.098,
Additional file 1: Figure S5).
In DFI analyses of untreated patients (n = 32, all stage II
from the validation set 1), low level of UPB1 (P = 0.026,
did not pass the correction for multiple testing) and
TYMP (P = 0.047, did not pass the correction for multiple
testing) significantly associated with worse DFI of patients
(Additional file 1: Figure S6).
Methylation levels in tumors and non-malignant adjacent
mucosa, associations with gene expression, and clinical
characteristics
Methylation of CpG islands in the regulatory regions of
all studied genes was initially studied in 22 pairs of
tumor and adjacent mucosa (testing set) and compared
with that from the independent validation set II. In the
both testing and validation II sets, methylation exceeding
the limit of quantitation was detected in DPYS, UPB1,
and uridine phosphorylase (UPP2, GeneID: 151531)
genes in both tumor and adjacent mucosa samples
(Table 2b, DPYS passed the correction for multiple test-
ing). Significantly elevated methylation level of DPYS was
recorded in tumor tissues compared to adjacent mucosa
in both sets (Table 2b). Methylation level of UPB1 was
lower in tumors than in adjacent mucosa in the testing
set, but not in the validation set II. No difference in pro-
moter methylation was observed for UPP2 in the testing
set by comparing tumors with non-malignant mucosa.
Methylation levels in promoter regions of DPYS or
UPB1 did not correlate with their corresponding tran-
script levels either in tumors or in adjacent mucosa sam-
ples analyzed in both sets. UPP2 transcript expression
was below the limit of quantification in both testing and
validation II sets suggesting that this gene is completely
silenced in colorectal tumors and corresponding adja-
cent mucosa tissues regardless clinical characteristics.
DPYS methylation level was associated with the tumor
stage in the testing set (P = 0.010, data not shown), but
not in the validation set II. Therefore, this association is
not further discussed. On the other hand, patients with
UPB1 methylation level below the median had signifi-
cantly worse DFI than those with the methylation level
above the median in both sets evaluated separately
(Additional file 1: Figure S7) and combined (n = 46,
P = 0.0002, passed the correction for multiple testing,
Fig. 3). This association was significant also in the
stage-adjusted analysis by Cox regression of the combined
set (n = 46, P = 0.004, HR = 9.22, 95 % CI = 2.04-41.57).
Combined analysis of UPB1 methylation in 5-FU treated
patients from testing and validation II sets failed to find
significant association with DFI (n = 32, P = 0.653, data
not shown). For DFI analyses, patients were divided into
two groups according to the median of methylation levels
in tumors. Methylation levels of DPYS and UPP2 have not
associated with the DFI of patients (P > 0.05).
Table 3 Differences in transcript levels in colorectal mucosa
between poor and good responders to 5-FU-based chemotherapy.
Transcript levels of 5-FU pathway genes were compared in
mucosas of patients in the testing set divided into groups
of poor responders (n = 13) and good responders (n = 13) to
the first line chemotherapy regimens based on 5-FU
Gene Expression level in poor responders vs. good responders
Fold differenceb Standard errorb P-valuea
DPYD 0.76 0.31–1.69 0.259
DPYS 0.91 0.10–6.89 0.434
PPAT 0.88 0.20–3.63 0.086
RRM2 0.31 0.11–1.46 0.038
RRM1 0.59 0.22–1.18 0.014
SLC29A1 0.76 0.17–2.73 0.369
TK1 0.87 0.18–3.66 0.157
TYMP 0.56 0.12–2.46 0.130
TYMS 0.82 0.15–3.77 0.121
UCK1 0.85 0.23–1.96 0.369
UCK2 0.74 0.17–2.42 0.681
UMPS 0.68 0.23–1.21 0.024
UPB1 0.91 0.26–2.85 0.479
UPP1 0.61 0.16–2.10 0.106
Footnotes:
aAnalyzed by the Mann-Whitney test
bFold changes and standard error calculated by the REST2009 program
Significant results in bold
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Protein levels in tumors and adjacent non-malignant
mucosa
DPYS and UPB1 protein levels were analyzed in a subset
of the testing set used for the methylation study, enab-
ling an evaluation of the cascade of methylation, gene,
and protein expression levels in colorectal cancer sam-
ples (Fig. 4). However, DPYS and UPB1 protein levels
did not significantly correlate either with their tran-
scripts or methylation levels (P > 0.05).
Discussion
The questions connected with prognostic importance of
molecular profile of 5-FU pathway in colorectal cancer re-
main attractive topics throughout last 15 years. Existing
Fig. 2 Association between RRM2 transcript levels and DFI of colorectal cancer patients. Kaplan-Meier survival curves were plotted for patients
(n = 66, one patient was lost to follow up) from the validation set I (a) or combined testing and validation I sets (n = 92) (b). Patients were divided
into two groups according to the median of transcript levels in tumors. Dashed line represents the group with lower transcript levels, solid line the
group with higher transcript levels than median. Differences between groups were compared using Log-rank test. All genes have been analyzed, but
to retain concise style only significant association is reported. HR = hazard ratio, 95 % CI = 95 % confidence intervals for stage-adjusted analyses
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studies offered a plethora of mostly conflicting results. The
absence of complex understanding, focused on mecha-
nisms of action underlying the most promising biomarkers
precludes their translation into clinical setting. Apparently,
the final prognostic scheme will integrate clinical factors,
e.g., stage and grade of the tumor with a cascade of
molecular markers involving genetic, epigenetic, and
phenotypic factors. The present study brings completely
new insight into this area by comprehensive molecular
profiling of major 5-FU pathway genes.
The present study shows for the first time that only
three (DPYS, UPB1, and UPP2) out of 15 evaluated 5-
Fig. 3 Association between UPB1 methylation levels and DFI of colorectal cancer patients. Kaplan-Meier survival curves were plotted for patients
from the both testing and validation II sets combined (n = 46). Seven stage IV patients were excluded and for further 31 patients data on methylation
or DFI were not available. Patients were divided into two groups according to the median of intratumoral gene methylation levels. Dashed
lines represent the group with lower methylation levels and solid lines represent the group with higher levels than median. Differences between these
groups were compared using Log-rank test. HR = hazard ratio, 95 % CI = 95 % confidence intervals for stage-adjusted analyses
Fig. 4 Protein expression of DPYS and UPB1 in tumors of colorectal cancer patients. Protein expression of DPYS (a) and UPB1 (b) was assessed
by immunoblotting with normalization to actin in the representative set of tumors with highest and lowest methylation levels as described in
Materials and Methods
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FU genes, are subject to notable methylation in tumor
and adjacent mucosa tissues.
Association of UPB1 promoter methylation with worse
prognosis of colorectal cancer patients, reported here on
two independent groups of patients and in the combined
set irrespective of 5-FU treatment, poses a completely
novel direction in pharmacogenomics of colorectal cancer.
UPB1 is an 5-FU inactivating enzyme [24], responsible for
degradation of pyrimidine bases (uracil and thymine) and
its genetic defect causes severe forms of propionic acide-
mia [25]. We hypothesized that a high UPB1 expression in
tumor cells caused by promoter demethylation could exert
a negative impact on the colorectal cancer patients re-
sponse to 5-FU. However, we did not prove such associ-
ation in the combined set of 5-FU treated patients and
moreover, UPB1 methylation level did not correlate with
either the transcript or the protein levels suggesting that its
prognostic role is most probably a complex phenomenon
involving some other factors. The lack of such correlation
may be explained by a number of effects, e.g., variation in
DNA folding in the studied region, regulation of target
gene by enhancers/silencers or by other than the followed
CpGs or control of gene expression by histone modifica-
tions. A more refined screening of CpG methylation in the
UPB1 surrounding area could provide more information
about potentially linked epigenetic changes. Moreover, the
function of the above mentioned gene may also be modu-
lated by microRNA interference (e.g., hsa-miR-216a, pre-
dicted by TargetScan).
From the genetic point of view it is intriguing that re-
cent study reported a strong association between the
rs2070474 polymorphism and gastrointestinal toxicity in
5-FU treated cancer patients [26]. It is of interest that
this polymorphism lies inside a large CpG island consist-
ing of 98 CpG sites [27] and near to the transcription
factor-binding motifs corresponding to a critical regula-
tor of the intestine, the CDX2 (caudal-type homeobox
transcription factor 2, OMIM: 600297 [28];). A potential
linkage of genetic with epigenetic changes thus should
also be considered.
On the basis of our gene expression data we may
generalize, that colorectal tumors irrespective of the stage
and localization share common downregulation of DPYD
and upregulation of PPAT, UMPS, RRM2, and SLC29A1
transcripts. RRM2 and UMPS upregulations and DPYD
downregulation in colorectal tumors comply with the previ-
ous study [29].
Interestingly, SLC29A1 was recently suggested as po-
tential co-determinant of clinical response to 5-FU [14]
and its upregulation demonstrated by the present study
further underpins the potential for targeted therapy of
colorectal cancer. On the basis of gene expression profile
we may deduce that chemotherapy-naïve colorectal can-
cer patients have in general favorable expression profile
shifted towards 5-FU activation (Fig. 5). A potential
change of this profile by chemotherapy or during meta-
static process presents another interesting question that
needs to be addressed.
Moreover, promoter of the 5-FU inactivating enzyme
DPYS was found hypermethylated in colorectal tumors
by this study. We thus confirmed the previously pub-
lished DPYS hypermethylation in colon carcinomas (and
breast and prostate carcinomas) compared with paired
normal tissues from the same patients [30]. Recently, it
Fig. 5 5-FU pathway genes evaluated by this study (adopted from [24])
Kunicka et al. BMC Cancer  (2016) 16:795 Page 9 of 12
was reported that differential methylation of DPYS
(and heat shock 27 kDa protein 1, HSPB1, OMIM:
602195 and cyclin D2, CCND2, OMIM: 123833) provides
independent prognostic information for prostate carcin-
oma [31]. Based on the present and earlier studies, colo-
rectal cancer-specific complex prognostic model based on
gene expression and methylation profile seems to deserve
further exploration.
Prognostic significance of low RRM2 transcript level
for poor colorectal cancer patient’s outcome observed by
the present study contradicts the previously published
data. High RRM2 level was poor survival predictor in
colorectal cancer patients [32] reflecting the established
in vitro ability of RRM2 to enhance cellular invasiveness
and genetic instability [33]. We cannot rule out that the
qPCR assay for RRM2 employed in the present study
also covered the RRM2B (OMIM: 604712) subunit
whose protein structure is 80 % identical to RRM2.
RRM2B intriguingly exerts opposite activity to RRM2
and its expression associates with a better survival of
colorectal cancer patients [34]. On the other hand,
RRM2 is 5-FU activating enzyme [24] and thus the re-
sult observed by us seems logical from this point of view
despite the fact that we have not observed a direct link
between prognostic role of RRM2 and 5-FU therapy
(perhaps due to the low number of the followed pa-
tients). Bearing in mind the issue of study size and pub-
licly available gene expression data, we analyzed the
prognostic power of RRM2 expression by SurvExpress
[35] tool using data from GSE12945 set (n = 947). A
borderline significant association towards higher risk
of shorter disease-free survival of the patients with
lower expression of RRM2 was apparent (p = 0.050,
Additional file 1: Figure S8).
The present study in line with other authors [9], has
not confirmed that overexpression of TYMS protein or
transcript predicts poor outcome in colorectal cancer
patients [7, 8]. Similarly, the results of studies indicating
potential prognostic role of DPYD [10, 11] or TYMP
[12] expression for survival of colorectal cancer patients
after 5-FU-treatment were not replicated.
The small sample size and small patient’s groups used
for DFI analyses, especially of patients treated with 5-FU
pose the major limitations of this study. Nevertheless, we
compared the methylation profiles with the publicly avail-
able database MethHC (Methylation and gene expression
in Human Cancer, http://methhc.mbc.nctu.edu.tw) inte-
grating gene expression, methylation, and microRNA ex-
pression data from The Cancer Genome Atlas (TCGA)
[36]. Our data complies with the results reported by this
database, i.e., the highest levels in UPP2, UPB1, and DPYS
(the rest of the genes below 25 %) and significantly higher
methylation of DPYS in tumor compared with mucosa
tissues (Additional file 1: Figure S9).
The variability among the patient cohorts could also
explain the lack of replication of some results. On the
other hand, the use of validation sets helped to achieve
more convincing interpretation of the replicated results
and where possible the analysis of combined sets in-
creased the study power. The lack of tissue aliquots for
simultaneous isolation of RNA and DNA necessitated
the use of two different validation sets. This fact pre-
cluded us to perform the otherwise preferable combined
analyses of both validation sets. Consequently, missing
data for comparison of methylation levels with DFI may
be seen as a study limitation.
Conclusions
In this study, we addressed importance of genes involved
in the 5-FU pathway for the prognosis of colorectal
cancer patients. In conclusion, chemotherapy-naïve
colorectal tumors seem to have favorable 5-FU pathway
gene expression profile. Additionally, low RRM2 gene
expression and UPB1 methylation level represent
treatment-independent poor prognostic factors for colo-
rectal carcinoma patients and should be further investi-
gated in relation to other epigenetic regulation pathways
(such as microRNAs) and in a complexity with other
relevant systems, such as DNA repair.
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Additional file 1: Table S1. Lists TaqMan Gene Expression Assays used
in the study. Table S2 shows sequence of primers and PCR conditions
used for promoter CpG methylation profiling. Table S3 shows results of
stage-adjusted Cox regression of associations between transcript levels
and DFI of colorectal cancer patients from the combined testing and
validation I sets. Figure S1 depicts 5-Fluorouracil pathway gene expression
levels in the studied sets of colorectal cancer patients. Figure S2 shows
results of analysis of associations between transcript levels and disease-free
survival of colorectal cancer patients from the validation set I. Figure S3
shows results of analysis of associations between transcript levels and dis-
ease-free survival of colorectal cancer patients from the testing set.
Figure S4 shows results of analysis of associations between transcript
levels and disease-free survival of colorectal cancer patients from the
combined testing and validation I set. Figure S5 shows results of
analysis of associations between transcript levels and disease-free
survival of 5-fluorouracil-treated colorectal cancer patients from the
combined testing and validation I set. Figure S6 shows results of
analysis of associations between transcript levels and disease-free
survival of untreated colorectal cancer patients from the validation I
set. Figure S7 shows results of analysis of associations between UPB1
methylation levels and disease-free survival of colorectal cancer patients.
Figure S8 shows analysis of association of RRM2 expression with
disease-free survival of colorectal cancer patients based on publicly
available GEO database. Figure S9 shows analysis of methylation
profiles of 5-FU pathway genes in human colorectal tumor (red boxes)
and mucosa (green boxes) tissues from publicly available MethHC database.
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